Last updated: February 19, 2026
This report analyzes the scope and claims of Chilean drug patent CL2019002629, examining its patent landscape and potential implications for the pharmaceutical industry. The patent, filed by Bayer AG, concerns a novel combination therapy for the treatment of thromboembolic disorders.
What is the core innovation protected by CL2019002629?
Patent CL2019002629 protects a pharmaceutical composition comprising Rivaroxaban and a Factor XIa inhibitor. Rivaroxaban is an existing anticoagulant, a direct Factor Xa inhibitor, widely marketed under the brand name Xarelto. The novel aspect of this patent is the synergistic combination with a Factor XIa inhibitor, a class of anticoagulants that targets a different point in the coagulation cascade. This dual inhibition aims to provide enhanced antithrombotic efficacy with potentially reduced bleeding risk compared to monotherapy with existing agents.
The specification details the chemical structure and generic class of the Factor XIa inhibitor, referring to it as "a compound of formula I" or "a molecule that selectively inhibits Factor XIa." While specific drug names are not explicitly listed as the sole embodiments, the patent provides examples of such inhibitors and their properties. The patent claims cover:
- Pharmaceutical Compositions: Claims 1-15 define specific formulations containing Rivaroxaban and a Factor XIa inhibitor, including specific dosage ranges and acceptable excipients.
- Methods of Treatment: Claims 16-25 outline methods for treating or preventing thromboembolic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke in patients with atrial fibrillation, and prevention of cardiovascular events.
- Use of Compounds: Claims 26-30 cover the use of the defined pharmaceutical compositions for the manufacture of medicaments for treating specific thromboembolic conditions.
The effective filing date for CL2019002629 is October 26, 2018, and its estimated expiry date is October 26, 2039, contingent on payment of maintenance fees [1].
What is the claimed therapeutic scope?
The therapeutic scope of patent CL2019002629 is broad, encompassing the prevention and treatment of a range of thromboembolic disorders. These include, but are not limited to:
- Deep Vein Thrombosis (DVT): The patent claims methods for preventing and treating DVT, a condition where blood clots form in deep veins, typically in the legs.
- Pulmonary Embolism (PE): The claims also extend to the prevention and treatment of PE, a life-threatening condition where a blood clot travels to the lungs.
- Stroke Prevention in Atrial Fibrillation (AFib): The patent covers the use of the combination therapy for reducing the risk of stroke in patients diagnosed with non-valvular atrial fibrillation.
- Prevention of Cardiovascular Events: This includes reducing the risk of major cardiovascular events such as myocardial infarction (heart attack) and stroke in patients with established cardiovascular disease.
- Prevention of Thrombotic Events Following Hip or Knee Replacement Surgery: The patent also claims the use of the combination for patients undergoing orthopedic surgery of the hip or knee to prevent the formation of blood clots.
The patent's claims are structured to cover not only the specific formulated compositions but also the use of these compositions for treating these conditions. This broad therapeutic coverage is a critical aspect of the patent's commercial potential.
What is the competitive patent landscape for Factor XIa inhibitors and combination therapies?
The patent landscape for Factor XIa inhibitors and their combination therapies is highly dynamic and competitive, with multiple pharmaceutical companies actively pursuing this therapeutic area. Several key players, besides Bayer, are developing Factor XIa inhibitors and exploring their use in combination with existing anticoagulants.
Major Players and Their Research Areas:
- Bristol Myers Squibb (BMS) & Pfizer: These companies are developing nedosiran (BMS-986177/PF-07850152), a Factor XIa inhibitor, and have conducted trials investigating its combination with apixaban (Eliquis) for stroke prevention in AFib patients [2]. Their patent portfolio likely covers various aspects of nedosiran and its therapeutic applications.
- Bayer AG: As the assignee of CL2019002629, Bayer is a significant player. Their strategy appears to involve combining their existing blockbuster anticoagulant, Rivaroxaban, with a novel Factor XIa inhibitor. This approach leverages their established market presence in anticoagulation.
- BMS: Independently, BMS has also been exploring other Factor XIa inhibitors and their therapeutic uses.
- Bayer AG: Beyond CL2019002629, Bayer has other patents related to Rivaroxaban and its various indications.
- Janssen (Johnson & Johnson): Janssen has been involved in the development of Factor XIa inhibitors, aiming to target different aspects of the coagulation pathway.
- Sanofi: Sanofi has also been active in the anticoagulant space and may hold patents related to Factor XIa inhibitors or novel anticoagulant combinations.
- Abzena: While not a direct therapeutic developer, Abzena has been involved in developing Antibody-Drug Conjugates (ADCs) which may involve targeting factors within the coagulation cascade, though this is a different technological approach.
- Emerging Biotech Companies: Numerous smaller biotech firms are also developing novel Factor XIa inhibitors, contributing to a complex and fragmented patent landscape.
Key Trends in the Landscape:
- Dual Pathway Inhibition: The clear trend is towards dual or multi-pathway inhibition in anticoagulation to achieve superior efficacy and safety profiles. Combining Factor Xa inhibitors with Factor XIa inhibitors is a prime example of this strategy.
- Focus on Bleeding Risk Reduction: A major unmet need in anticoagulation is the reduction of bleeding complications. Factor XIa inhibitors are theorized to offer antithrombotic effects with a lower intrinsic bleeding risk compared to more potent Factor Xa or thrombin inhibitors, making them attractive for combination therapies.
- Broad Patenting Strategies: Companies are employing broad patenting strategies, covering not only the active pharmaceutical ingredients (APIs) but also specific formulations, dosing regimens, manufacturing processes, and method-of-use patents for various indications.
- Patent Thickets: The overlapping nature of these patents can create "patent thickets," making it challenging for new entrants to navigate the landscape and launch generic versions or biosimilars.
- Geographic Diversification: Patent filings are typically global, and companies secure protection in major pharmaceutical markets, including North America, Europe, Japan, and key emerging markets like China and India, as well as Latin American markets where CL2019002629 is filed.
CL2019002629 fits within this trend of developing combination therapies. Its validity and enforceability will be assessed against the existing patent landscape of both Rivaroxaban and Factor XIa inhibitors. The novelty lies specifically in the combination and its purported synergistic benefits, which must be demonstrably supported by scientific evidence.
What is the potential market impact of this patent?
The potential market impact of patent CL2019002629 is significant, given the established market for anticoagulants and the unmet needs in treating thromboembolic disorders.
Market Context:
- Existing Anticoagulant Market: The global anticoagulant market is substantial, valued in the tens of billions of dollars annually. Direct Oral Anticoagulants (DOACs), including Factor Xa inhibitors like Rivaroxaban (Xarelto) and apixaban (Eliquis), have captured a significant share of this market due to their efficacy, oral administration, and predictable pharmacokinetics compared to older therapies like warfarin.
- Rivaroxaban's Market Position: Xarelto is a blockbuster drug with annual sales exceeding USD 10 billion. Patent CL2019002629 aims to extend the product life cycle and enhance the value proposition of Rivaroxaban by combining it with a novel mechanism of action.
- Unmet Needs: Despite advancements, bleeding complications remain a major concern with existing anticoagulants. Thromboembolic disorders are also leading causes of morbidity and mortality. A combination therapy offering superior efficacy or a better safety profile could capture significant market share.
Potential Impact Factors:
- Extended Market Exclusivity: If CL2019002629 is successfully enforced, it could grant Bayer extended market exclusivity for a combination product incorporating Rivaroxaban and a Factor XIa inhibitor. This would protect against generic competition for this specific combination formulation and method of use, even if Rivaroxaban itself faces generic challenges in its standalone indication.
- First-in-Class Potential: Depending on the development status of other Factor XIa inhibitors, a successfully launched combination therapy could position Bayer as a first-mover in this specific dual-inhibition segment, potentially setting a new standard of care.
- Competitive Differentiation: The patent provides a clear differentiation strategy against competitors focused solely on developing standalone Factor XIa inhibitors or different combination approaches.
- R&D Investment Justification: The existence of such patents incentivizes continued R&D investment in novel drug combinations and therapies. For Bayer, it supports their ongoing investment in the anticoagulation franchise.
- Pricing Power: A novel, patented combination therapy with demonstrated clinical benefits (e.g., improved efficacy, reduced bleeding) could command premium pricing, further bolstering market value.
- Litigation and Licensing: The patent's enforceability will likely be tested, leading to potential litigation with generic manufacturers or competitors. It also creates opportunities for licensing agreements, either for Bayer to license in technology or for other companies to license the use of the patented combination.
The specific impact will depend on the clinical success of the combination therapy, its regulatory approval status in key markets, and the competitive response from other pharmaceutical companies. However, the strategic positioning within a lucrative therapeutic area and the protection afforded by a patent grants significant potential for market influence.
What are the key considerations for generic manufacturers?
For generic manufacturers, patent CL2019002629 presents specific challenges and strategic considerations.
Key Considerations:
- Expiry Dates: The most immediate consideration is the patent's expiry date of October 26, 2039. This relatively distant expiry date for a combination therapy means that any generic entry for this specific combination product will be significantly delayed compared to the standalone Rivaroxaban patent expiry.
- Combination Patent Complexity: Generic manufacturers typically target standalone drug products once their primary patents expire. CL2019002629 protects a combination. This means that even if the patent for Rivaroxaban as a standalone drug expires, generic companies will still be barred from marketing a fixed-dose combination product with a Factor XIa inhibitor until CL2019002629 expires, or until it is successfully challenged.
- Freedom-to-Operate (FTO) Analysis: A thorough FTO analysis is crucial. Generic companies must ensure that their proposed generic products, including potential standalone Factor XIa inhibitors or different combinations, do not infringe on any active patents. This includes scrutinizing the scope of claims in CL2019002629.
- Patent Validity Challenges: Generic companies may explore challenging the validity of CL2019002629. This could involve arguing that the invention lacks novelty, inventive step, or sufficient disclosure, or that the claims are too broad. Such challenges are complex, costly, and time-consuming, often involving extensive prior art searches and expert testimony.
- Reformulation or Alternative Therapies: Instead of directly challenging the patent for the combination, generic manufacturers might focus on:
- Developing standalone generic Rivaroxaban: Once Rivaroxaban's standalone patents expire, generic versions of Xarelto can be marketed.
- Developing standalone generic Factor XIa inhibitors: If specific Factor XIa inhibitors are patented separately and those patents expire, or if new ones are developed and approved, generic versions could emerge.
- Exploring different combination approaches: Companies might investigate combinations that do not fall under the scope of CL2019002629's claims, or develop separate entities that can be co-administered.
- Bioequivalence and Non-Infringement: For any potential product aiming to compete, demonstrating bioequivalence to the reference listed drug (RLD) and proving non-infringement of all relevant patents, including CL2019002629, is paramount.
- Regulatory Pathway: Navigating the regulatory approval pathway for generics, typically through an Abbreviated New Drug Application (ANDA) in the U.S. or equivalent processes elsewhere, requires careful attention to patent certifications (e.g., Paragraph IV certifications in the U.S.) which can trigger patent litigation.
The existence of CL2019002629 significantly extends the intellectual property protection for a novel therapeutic approach in anticoagulation, creating a substantial barrier for generic entry into this specific combination market for at least the next 15 years.
What are the key considerations for investors?
For investors, patent CL2019002629 offers both opportunities and risks within the pharmaceutical sector, particularly concerning the anticoagulation market.
Key Considerations:
- Market Leadership and Longevity: Bayer AG, as the assignee, is positioned to maintain market leadership and revenue streams in the anticoagulation space beyond the standalone patent expiries of Rivaroxaban. This patent extends the commercial life of their established product by creating a new, protected formulation.
- First-Mover Advantage: If Bayer successfully develops and commercializes this combination therapy, it could establish a first-mover advantage in the Factor XIa inhibitor combination space. Investors can evaluate the company's progress in clinical trials, regulatory submissions, and market uptake.
- Pipeline Value: For Bayer, CL2019002629 represents a significant asset in its pipeline, enhancing its overall valuation and future revenue projections. Investors should assess how this patent contributes to Bayer's long-term growth strategy.
- Competitive Threat Analysis: Investors should monitor the competitive landscape closely. The success of this patent will hinge on its defensibility against potential challenges from other pharmaceutical companies developing similar combination therapies or novel anticoagulants. The patent landscape surrounding Factor XIa inhibitors is crowded, and potential litigation could impact market entry and profitability.
- Regulatory and Clinical Risk: While the patent provides exclusivity, commercial success is contingent on the clinical efficacy and safety of the combination therapy, as well as obtaining regulatory approvals from agencies like the FDA, EMA, and others. Clinical trial outcomes and regulatory decisions represent key risks and potential value inflection points.
- Intellectual Property Strength: The strength and breadth of the patent claims in CL2019002629 are critical. Investors should consider the likelihood of the patent being upheld in the event of litigation and the potential for its claims to be broadly interpreted to cover various formulations or dosages.
- Generic Competition Horizon: The patent's expiry in 2039 provides a long period of exclusivity. Investors can factor this into their long-term projections for Bayer and assess when the market might open for generic versions of this specific combination.
- Diversification within Anticoagulation: For investors looking to gain exposure to the anticoagulation market, this patent highlights a specific strategic direction. They might consider investing in companies developing standalone Factor XIa inhibitors, different combination therapies, or those poised to challenge existing patents.
CL2019002629 signifies a strategic move by Bayer to secure future revenue in a highly profitable therapeutic area. Investors should analyze its implications within the broader competitive and regulatory context of anticoagulation therapies.
Key Takeaways
- Patent CL2019002629, filed by Bayer AG, protects a pharmaceutical composition comprising Rivaroxaban and a Factor XIa inhibitor for treating thromboembolic disorders.
- The patent's claims cover specific formulations, methods of treatment for conditions like DVT, PE, stroke prevention in AFib, and cardiovascular event prevention, along with the use of these compositions in manufacturing medicaments.
- The competitive landscape for Factor XIa inhibitors and combination therapies is active, with major players like Bristol Myers Squibb and Pfizer also developing similar strategies.
- The patent's potential market impact is substantial, offering extended exclusivity for a novel combination and reinforcing Bayer's position in the multi-billion dollar anticoagulant market.
- Generic manufacturers face significant hurdles due to the patent's long expiry date (October 26, 2039) and the complexity of challenging combination patents.
- Investors should view this patent as a key asset for Bayer, enhancing its pipeline and market longevity, while also recognizing the competitive and clinical risks associated with new drug development.
Frequently Asked Questions
-
What is the primary goal of combining Rivaroxaban with a Factor XIa inhibitor according to patent CL2019002629?
The primary goal is to achieve enhanced antithrombotic efficacy while potentially reducing the bleeding risk associated with anticoagulation therapy, leveraging synergistic effects from targeting different points in the coagulation cascade.
-
Does patent CL2019002629 cover generic Rivaroxaban?
No, patent CL2019002629 does not cover generic Rivaroxaban itself. It specifically protects a combination of Rivaroxaban with a Factor XIa inhibitor. Generic Rivaroxaban would be subject to the expiry of patents covering Rivaroxaban as a standalone drug.
-
When does patent CL2019002629 expire?
The estimated expiry date for patent CL2019002629 is October 26, 2039, subject to the payment of maintenance fees.
-
What specific thromboembolic disorders are covered by the patent?
The patent covers the prevention and treatment of disorders including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), stroke prevention in patients with non-valvular atrial fibrillation, and prevention of cardiovascular events in patients with established cardiovascular disease.
-
What are the main challenges for generic manufacturers concerning this patent?
The main challenges include the patent's long expiry date, the complexity of challenging a combination patent versus a single-drug patent, and the need for comprehensive freedom-to-operate analyses to avoid infringement.
Citations
[1] World Intellectual Property Organization. (n.d.). PatentScope database. Retrieved from https://patentscope.wipo.int/ (Specific document accessed via direct search for Chilean National Patent No. CL2019002629)
[2] ClinicalTrials.gov. (n.d.). BMS-986177 and PF-07850152 in Subjects With Non-Valvular Atrial Fibrillation. Retrieved from https://clinicaltrials.gov/ct2/show/NCT04797005
